Deerfield Management Company, L.P. (Series C) Werewolf Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.65 $9.12 Million - $14 Million	-794,662 Reduced 45.34%	958,125 $11.4 Million
Q3 2021 Nov 15, 2021	SELL	$13.89 - $20.31 $11.1 Million - $16.2 Million	-800,000 Reduced 31.34%	1,752,787 $30.1 Million
Q2 2021 Aug 16, 2021	BUY	$11.6 - $17.44 $29.6 Million - $44.5 Million	2,552,787 New	2,552,787 $44.5 Million

Others Institutions Holding HOWL

# of Institutions

Shares Held

31.8M

Call Options Held

700

Put Options Held

500

Ra Capital Management, L.P. Boston, MA

6.14M
Shares

$9.77 Million
0.18% of portfolio
Mpm Asset Management LLC Cambridge, MA

4.28M
Shares

$6.81 Million
6.25% of portfolio
Pfm Health Sciences, LP San Francisco, CA

3.4M
Shares

$5.4 Million
0.42% of portfolio
Bio Impact Capital LLC Cambridge, MA

2.39M
Shares

$3.8 Million
0.79% of portfolio
Bank Of America Corp Charlotte, NC

2.15M
Shares

$3.42 Million
0.0% of portfolio

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $47M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account